Study Summary
This trial will compare the effectiveness of two different combinations of drugs for treating patients with multiple myeloma who have received at least one prior therapy.
- Multiple Myeloma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 16 Secondary · Reporting Duration: Up to 9 years
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Daratumumab SC, Lenalidomide, and Dexamethasone (DRd)
1 of 2
Teclistamab, Daratumumab SC, Lenalidomide (Tec-DR)
1 of 2
Experimental Treatment
1030 Total Participants · 2 Treatment Groups
Primary Treatment: Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 23rd, 2021
Last Reviewed: November 15th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.